{"id":2227,"date":"2017-12-04T10:58:00","date_gmt":"2017-12-04T02:58:00","guid":{"rendered":"https:\/\/tcr.cph.ntu.edu.31app.tw\/?p=2227"},"modified":"2022-01-22T11:13:53","modified_gmt":"2022-01-22T03:13:53","slug":"%e7%99%8c%e7%99%bb%e7%ac%ac106005%e8%99%9f%e9%80%9a%e7%9f%a5%e6%96%87-%e5%9b%a0%e6%87%89107%e5%b9%b4%e7%99%8c%e7%97%87%e7%99%bb%e8%a8%98%e5%af%a6%e5%8b%99%e4%bd%9c%e6%a5%ad%e4%b9%8b%e9%9c%80","status":"publish","type":"post","link":"https:\/\/twcr.tw\/?p=2227","title":{"rendered":"[\u764c\u767b\u7b2c106005\u865f\u901a\u77e5\u6587] \u56e0\u61c9107\u5e74\u764c\u75c7\u767b\u8a18\u5be6\u52d9\u4f5c\u696d\u4e4b\u9700\u6c42\uff0c\u8acb \u8cb4\u9662\u4f9d\u8aaa\u660e\u6bb5\u8fa6\u7406"},"content":{"rendered":"

\u4e00\u3001\u672c\u6848\u4fc2\u4f9d\u885b\u751f\u798f\u5229\u90e8\u570b\u6c11\u5065\u5eb7\u7f72\u59d4\u8a17\u300c\u53f0\u7063\u764c\u75c7\u767b\u8a18\u5de5\u4f5c\u8a08\u756b\u300d\u8fa6\u7406\u3002<\/p>\n

\n

\u00a0\u4e8c\u3001\u56e0\u61c9\u63d0\u5347\u5168\u570b\u764c\u75c7\u767b\u8a18\u7533\u5831\u6642\u6548\u6027\uff0c\u81ea107\u5e74\u8d77\u91ab\u9662\u7dda\u4e0a\u7533\u5831\u6642\u7a0b\u5c07\u63d0\u524d\u4e00\u500b\u6708\uff0c\u5373\u6539\u70ba\u6bcf2\u30015\u30018\u300111\u6708\u4efd\u8d77\u958b\u653e\u7533\u5831\u3002<\/p>\n

\n

\u4e09\u3001\u81ea107\u5e74\u8d77\uff0c\u6240\u6709\u8a3a\u65b7\u5e74\u5ea6\u500b\u6848\u5747\u5168\u9762\u63a1\u7528\u4e0b\u8ff0106\u5e74\u4fee\u8a02\u7248\u7533\u5831\u3002\u53e6105\u8a3a\u65b7\u5e74\u4ecd\u9700\u7533\u5831\u500b\u6848\uff0c\u53ef\u6cbf\u7528105\u5e74\u4fee\u8a02\u7248\u672c\u7533\u5831\uff0c\u4f46\u5fc5\u9808\u65bc106\u5e7412\u670831\u65e5\u524d\u4f9d\u6cd5\u5b8c\u6210\u7533\u5831\u3002<\/p>\n

\u56db\u3001\u300c100\u5e74\u7248\u53f0\u7063\u764c\u75c7\u767b\u8a18\u6458\u9304\u624b\u518a\u300d- 106\u5e74\u4fee\u8a02\u7248\u53ca\u300c\u764c\u75c7\u90e8\u4f4d\u7279\u5b9a\u56e0\u5b50\uff08SSF\uff09\u7de8\u78bc\u624b\u518a\u300d- 106\u5e74\u4fee\u8a02\u7248\uff0c\u696d\u7531\u5404\u91ab\u9662\u60e0\u793a\u610f\u898b\u4e26\u4f9d\u64da\u5c08\u5bb6\u6703\u8b70\u8a0e\u8ad6\u5f8c\u4fee\u8a02\u5b8c\u7ae3\uff0c\u4fee\u8a02\u7248\u4e4b\u9644\u9304\u4fee\u8a02\u8655\u6709\u8a73\u7d30\u66f4\u65b0\u8aaa\u660e\uff0c\u63d0\u4f9b\u91ab\u9662\u53c3\u8003\u3002
\n\u5b8c\u6574\u4fee\u8a02\u7248\u6a94\u6848\u8acb\u9015\u81f3\u53f0\u7063\u764c\u75c7\u767b\u8a18\u4e2d\u5fc3\u7db2\u7ad9\u4e0b\u8f09\uff0c\u7db2\u5740\u5982\u4e0b\uff1a
\nhttp:\/\/tcr.cph.ntu.edu.tw\/main.php?Page=A6<\/a>\u3002<\/p>\n

\u4e94\u3001\u300c100\u5e74\u7248\u53f0\u7063\u764c\u75c7\u767b\u8a18\u6458\u9304\u624b\u518a\u300d\u8207\u300c\u764c\u75c7\u90e8\u4f4d\u7279\u5b9a\u56e0\u5b50\uff08SSF\uff09\u7de8\u78bc\u624b\u518a\u300d-106\u5e74\u4fee\u8a02\u7248\u91cd\u8981\u4fee\u6b63\u6458\u8981\u5982\u4e0b\uff0c\u8a73\u7d30\u5167\u5bb9\u8acb\u53c3\u8003106\u5e74\u4fee\u8a02\u7248\u624b\u518a\uff1a<\/p>\n

    \n
  1. \u5176\u4ed6\u5206\u671f\u7cfb\u7d71\u671f\u5225(\u81e8\u5e8a)(\u764c\u767b\u6b04\u4f4d\u5e8f\u865f#3.19)\uff1a\u4fee\u6539DRE\u7de8\u78bc\u6b04\u4f4dTX\u4e4b\u5b9a\u7fa9\uff0c\u201c\u7121\u6cd5\u8a55\u4f30\u201d\u6539\u70ba\u201c\u7121\u809b\u3001\u8853\u5f8c\u78ba\u8a3a\u6216\u5176\u4ed6\u56e0\u7d20\u7121\u6cd5\u57f7\u884cDRE\u201d\u3002<\/li>\n
  2. \u539f\u767c\u90e8\u4f4d\u624b\u8853\u908a\u7de3(\u764c\u767b\u6b04\u4f4d\u5e8f\u865f#4.1.5)\uff1a\u65b0\u589e\u7de8\u78bc\u6307\u5f15\u7b2c\u516d\u9ede\uff1a\u651d\u8b77\u817a\u764c\u500b\u6848\u50c5\u63a5\u53d7TURP(\u8853\u5f0f\u7de8\u78bc\u70ba21-23)\uff0c\u672c\u6b04\u4f4d\u61c9\u7de8\u78bc\u70ba8\u3002\u539f\u7b2c\u516d\u9ede\u79fb\u81f3\u7b2c\u4e03\u9ede\u3002<\/li>\n
  3. \u653e\u5c04\u6cbb\u7642\u5100\u5668(\u764c\u767b\u6b04\u4f4d\u5e8f\u865f#4.2.1.2)\u3001\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\u6280\u8853(\u764c\u767b\u6b04\u4f4d\u5e8f\u865f#4.2.2.1)\u3001\u5176\u4ed6\u653e\u5c04\u6cbb\u7642\u6280\u8853(\u764c\u767b\u6b04\u4f4d\u5e8f\u865f#4.2.3.2)\uff1a\u4fee\u6539\u7de8\u78bc\u6307\u5f15\uff1a\u82e5\u6cbb\u7642\u5100\u5668\u63cf\u8ff0\u70baSBRT (Stereotatic Body Radiotherapy)\u6216SABR (Stereotatic Ablative Body Radiotherapy)\uff0c\u4e14\u6cbb\u7642\u6280\u8853\u4f7f\u7528\u8afe\u529b\u5200(Norvalis)\u3001\u5f37\u5ea6\u8abf\u63a7\u653e\u5c04\u6cbb\u7642(IMRT)\u3001\u9ad4\u7a4d\u5f27\u5f62\u653e\u5c04\u6cbb\u7642(Rapid Arc\u00ae)\u6216\u8cea\u5b50(Proton)\u6642\uff0c\u4f9d\u64da\u6cbb\u7642\u6b21\u6578(Fraction \/ Session)\u53ca\u5291\u91cf\u5340\u5206\u653e\u5c04\u624b\u8853\u6216\u9ad4\u5916\u653e\u5c04\u6cbb\u7642\uff1a\u6cbb\u7642\u6b21\u6578\u22666\u4e14\u5291\u91cf\u2267800 cGy\/\u6b21\u8996\u70ba\u653e\u5c04\u624b\u8853\uff1b\u6cbb\u7642\u6b21\u6578>6\u6b21\u6216\u5291\u91cf\uff1c800 cGy\/\u6b21\uff0c\u5247\u767b\u9304\u70ba\u9ad4\u5916\u653e\u5c04\u7dda\u6cbb\u7642\u3002<\/li>\n
  4. \u5176\u4ed6\u653e\u5c04\u6cbb\u7642\u6280\u8853(\u764c\u767b\u6b04\u4f4d\u5e8f\u865f#4.2.3.2)\uff1a\u65b0\u589e\u653e\u5c04\u624b\u8853\u5c08\u7528\u7de8\u78bc\u6b04\u4f4d6\u53ca\u5b9a\u7fa9\uff1a\u653e\u5c04\u624b\u8853\u53ea\u7528\u7acb\u9ad4\u5b9a\u4f4d\u8cea\u5b50\u6cbb\u7642\u3002<\/li>\n
  5. \u6b7b\u4ea1\u539f\u56e0(\u764c\u767b\u6b04\u4f4d\u5e8f\u865f#5.6)\uff1a\u4fee\u6b63\u7de8\u78bc\u6307\u5f15\u7b2c\u56db\u9ede\uff1a\u82e5\u81f4\u6b7b\u764c\u75c7\u70ba\u591a\u767c\u764c\u75c7\uff0c\u4e14\u7121\u6cd5\u78ba\u8a8d\u6b7b\u65bc\u5176\u4e2d\u4f55\u7a2e\u764c\u75c7\u6642\uff0c\u8acb\u7de8\u78bcC97 (Malignant neoplasms of independent (primary) multiple sites)\u3002<\/li>\n
  6. \u65b0\u589e\u9644\u9304F\uff1a\u764c\u767b\u4e2d\u5fc3\u901a\u77e5\u6587\u91cd\u8981\u516c\u544a\u4e8b\u9805\u6458\u9304\u3002<\/li>\n
  7. \u98df\u9053\u764cSSF1\u6b63\u5b50\u6383\u63cf\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\uff1a\u522a\u9664\u7de8\u78bc\u6b04\u4f4d010\u3001011\u4e4b\u5b9a\u7fa9\u53ca\u65b0\u589e020\u3001030\u3001040\u4e4b\u5b9a\u7fa9\uff1a<\/li>\n<\/ol>\n\n\n\n\n\n\n\n\n\n
    \u7de8\u78bc<\/strong><\/td>\n\u5b9a\u7fa9<\/strong><\/td>\n<\/tr>\n
    000<\/td>\n\u7121\u4f7f\u7528\u6b63\u5b50\u6383\u63cf\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002<\/td>\n<\/tr>\n
    010<\/s><\/td>\n\u6709\u4f7f\u7528\u6b63\u5b50\u6383\u63cf\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002<\/s><\/td>\n<\/tr>\n
    011<\/s><\/td>\n\u4f7f\u7528\u6b63\u5b50\u6383\u63cf<\/s>(PET<\/s>\uff0c\u975e<\/s>PET-CT<\/s>\u6b63\u5b50\u6383\u63cf\u96fb\u8166\u65b7\u5c64<\/s>)<\/s>\u6aa2\u67e5\u3002<\/s><\/td>\n<\/tr>\n
    020<\/td>\n\u50c5\u9996\u6b21\u6cbb\u7642\u524d\u6709\u4f7f\u7528\u6b63\u5b50\u6383\u63cf\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002<\/td>\n<\/tr>\n
    030<\/td>\n\u50c5\u9996\u6b21\u6cbb\u7642\u5f8c\u6709\u4f7f\u7528\u6b63\u5b50\u6383\u63cf\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002<\/td>\n<\/tr>\n
    040<\/td>\n\u9996\u6b21\u6cbb\u7642\u524d\u5f8c\u5747\u6709\u4f7f\u7528\u6b63\u5b50\u6383\u63cf\u96fb\u8166\u65b7\u5c64\u6aa2\u67e5\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
      \n
    1. \u80c3\u764c<\/strong>SSF1-5\u65b0\u589e\u4e0d\u9069\u7528\u7d44\u7e54\u578b\u614b\u7de8\u78bc\uff1aNETs (ICD-O-3 M-8153, 8240-8242, 8246, 8249)\uff1b\u4e14\u65b0\u589e\u6536\u9304\u6b04\u4f4dSSF 4<\/strong>\uff1a\u75c5\u7406\u5207\u7247\u4e2d\u7684\u816b\u7624\u6df1\u5ea6\u3001<\/strong>SSF 5<\/strong>\uff1a\u6dcb\u5df4\u7ba1\u6216\u8840\u7ba1\u4fb5\u72af<\/strong>\u3002<\/li>\n
    2. \u80ba\u764c<\/strong>\u65b0\u589e\u6536\u9304\u6b04\u4f4dSSF 7<\/strong>\uff1a<\/strong>ALK<\/strong>\u57fa\u56e0\u8f49\u4f4d\u7a81\u8b8a<\/strong>\u3002<\/li>\n
    3. \u4e73\u764cSSF1,2,7\u65b0\u589e\u4e0d\u9069\u7528\u7d44\u7e54\u578b\u614b\u7de8\u78bc\uff1aPhyllodes tumors (ICD-O-3 M-9020)\u3002<\/li>\n
    4. \u651d\u8b77\u817a\u764cSSF1\u651d\u8b77\u817a\u7279\u7570\u6297\u539f\u6307\u6578\u65b0\u589e\u7de8\u78bc\u6307\u5f15\uff1a\u500b\u6848\u5206\u985e\u70ba<\/strong>0-2<\/strong>\u8005<\/strong>\uff0c\u5747\u9808\u8a18\u8f09\u651d\u8b77\u817a\u7279\u7570\u6297\u539f\u6307\u6578(PSA)\u6700\u9ad8\u503c\u3002<\/li>\n<\/ol>\n

      \u516d\u3001\u4f9d\u64da\u6700\u65b0WHO Classification of Head and Neck Tumours\u00a0(2017)\u3001WHO Classification of Tumours of Endocrine Organs\u00a0(2017)\u5f59\u6574\u800c\u6210\uff0c\u56e02000\u5e74\u51fa\u7248\u4e4bICD-O-3\u7de8\u78bc\u4e0d\u6577\u4f7f\u7528\uff0c\u4e14\u73fe\u884c\u75c5\u7406\u5831\u544a\u6309\u6700\u65b0\u7d44\u7e54\u578b\u614b\u8a18\u8f09\uff0c\u6545\u63d0\u4f9b\u6700\u65b0\u75c5\u7406\u7d44\u7e54\u578b\u614b\u7de8\u78bc\u4f9b\u91ab\u9662\u4f7f\u7528\u00a0(\u9644\u4ef6\u66f4\u65b0\u81ea\u764c\u767b105001\u865f\u901a\u77e5\u6587\u5167\u5bb9)\uff0c\u6ce8\u610f\u4e8b\u9805\u5982\u4e0b\uff1a<\/p>\n

        \n
      1. \u80f0\u81df\u7684\u5167\u5206\u6ccc\u816b\u7624\uff1aInsulinoma\u3001Glucagonoma\u3001Gastrinoma\u3001Somatostatinoma\u3001VIPoma\u3001ACTH-producing tumour (C25._)\uff0c\u8207Pheochromocytoma (C74.1)\u3001Carotid body paraganglioma (C75.4)\u3001Middle ear paraganglioma (C75.5)\uff0c\u4ee5\u53caEpithelioid hemangio-endothelioma (C30.0, C31._)\uff0c\u81ea106\u8a3a\u65b7\u5e74\u8d77\u7686\u8996\u70ba\u60e1\u6027\uff0c\u9700\u7533\u5831\u3002<\/li>\n
      2. Sellar ependymoma (C75.1)\u8207Immature teratoma (grade 2) (C73.9)\u81ea106\u8a3a\u65b7\u5e74\u8d77\u61c9\u8996\u70ba\u826f\u6027\uff0c\u4e0d\u9700\u7533\u5831\uff1b\u4f46Malignant teratoma (grade 3) (C73.9)\u00a0\u4ecd\u61c9\u7533\u5831\u3002<\/li>\n
      3. Chondrosarcoma, NOS\u8207Chondrosarcoma, grade 2\/3\u7de8\u78bc\u70ba9220\/3\u9700\u7533\u5831\uff1b\u65b0\u589eChondrosarcoma, grade 1\u7de8\u78bc\u70ba9222\/1\uff0c\u4e0d\u9700\u7533\u5831\u3002<\/li>\n
      4. \u65b0\u589e\u7de8\u78bcSquamous cell carcinoma, HPV-positive 8085\/3\u8207Squamous cell carcinoma, HPV-negative 8086\/3 (C01.9, C09._, \u00a0C10._)\u3002<\/li>\n<\/ol>\n<\/div>\n<\/div>\n

        \u4e03\u3001\u00a0\u518d\u6b21\u63d0\u9192<\/strong>\uff1a\u6700\u65b0AJCC Cancer Staging Manual 8th Edition\u5df2\u65bc2016\u5e74\u5e95\u516c\u5e03\uff0c\u5c07\u9069\u7528\u65bc2018\u5e741\u67081\u65e5\u8d77\u65b0\u8a3a\u65b7\u4e4b\u764c\u75c7\u500b\u6848\uff0c\u4e26\u65bc2019\u5e74\u00a0(\u6c11\u570b108\u5e74)\u8d77\u958b\u59cb\u7533\u5831\u3002\u6709\u95dcAJCC\u7b2c\u516b\u7248\u6700\u65b0\u5167\u5bb9\u6216\u52d8\u8aa4\u8868\uff0c\u8acb\u53c3\u95b1\u4e0b\u5217\u7db2\u5740\uff1a<\/p>\n

        \n
        https:\/\/cancerstaging.org\/references-tools\/deskreferences\/Pages\/default.aspx<\/a><\/u><\/div>\n<\/div>\n
        \n
        <\/div>\n<\/blockquote>\n

        [\u00a0\u764c\u767b\u7b2c106005\u865f\u901a\u77e5\u6587\u5168\u6587\u4e0b\u8f09<\/a>\u00a0]<\/p>\n","protected":false},"excerpt":{"rendered":"

        \u4e00\u3001\u672c\u6848\u4fc2\u4f9d\u885b\u751f\u798f\u5229\u90e8\u570b\u6c11\u5065\u5eb7\u7f72\u59d4\u8a17\u300c\u53f0 … <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-2227","post","type-post","status-publish","format-standard","hentry","category-lastsnews"],"_links":{"self":[{"href":"https:\/\/twcr.tw\/index.php?rest_route=\/wp\/v2\/posts\/2227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/twcr.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/twcr.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/twcr.tw\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/twcr.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2227"}],"version-history":[{"count":1,"href":"https:\/\/twcr.tw\/index.php?rest_route=\/wp\/v2\/posts\/2227\/revisions"}],"predecessor-version":[{"id":2246,"href":"https:\/\/twcr.tw\/index.php?rest_route=\/wp\/v2\/posts\/2227\/revisions\/2246"}],"wp:attachment":[{"href":"https:\/\/twcr.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/twcr.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/twcr.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}